Start Your Search
Yoon Soo Chang
EP1.01 - Advanced NSCLC (ID 150)
- Event: WCLC 2019
- Type: E-Poster Viewing in the Exhibit Hall
- Track: Advanced NSCLC
- Presentations: 1
- Now Available
- Coordinates: 9/08/2019, 08:00 - 18:00, Exhibit Hall
EP1.01-11 - Prognosis of Lung Cancer in Patients with Interstitial Lung Disease; Comparison with NSIP and IPF (Now Available) (ID 1307)
08:00 - 18:00 | Author(s): Yoon Soo Chang
Lung cancer is the leading cause of death in worldwide. Some reports revealed that lung cancer with interstitial lung disease (ILD) is associated with poor prognosis. However, the prognosis of lung cancer according to the subtype of ILD is unclear. We analyzed the outcome of lung cancer according to CT findings of ILD.
Among the non-small cell lung cancer (NSCLC) patients who visited Severance Hospital, Seoul, Korea from July 2005 to October 2018, patients with idiopathic pulmonary fibrosis (IPF) or non-specific interstitial pneumonia (NSIP) in chest CT image were enrolled in this study. Patients were divided into three groups according to CT findings; (1) definite + possible IPF, (2) intermediate, and (3) definite NISP + possible NSIP. All patients were diagnosed lung cancer NSCLC on biopsy. The characteristics of study population and prognosis of each group were examinedResult
A total of 151 patients were investigated in this study. Female was 4.6% and mean age was 70.2 years. 84 patients were definite + possible IPF group, 42 patients were intermediate, and 25 patients were definite NISP + possible NSIP group. The proportion of smokers who smoked once was significantly higher in definite + possible IPF group (p=0.006). Age, FVC, FEV1 and lung cancer stage were not different between the three groups. Median overall survival were 27.0 months in NSIP group, 15.3 months in intermediate group, and 9.5 months in IPF group (p=0.04). Additionally, 25% of patients in definite + possible IPF group experienced acute exacerbation.Conclusion
CT findings of ILD in lung cancer patients could be helpful in predicting prognosis. Furthermore, acute exacerbation is more common in IPF patients. Therefore, careful attention should be paid to the treatment of lung cancer in patients with IPF pattern.
Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.
P1.09 - Pathology (ID 173)
- Event: WCLC 2019
- Type: Poster Viewing in the Exhibit Hall
- Track: Pathology
- Presentations: 1
- Coordinates: 9/08/2019, 09:45 - 18:00, Exhibit Hall
P1.09-14 - Comparison Between Liquid Biopsy and Conventional Tissue Biopsy in EGFR Genotyping of Non-Small Cell Lung Cancer (ID 978)
09:45 - 18:00 | Author(s): Yoon Soo Chang
In lung cancer, tissue biopsy is usually invasive and could provoke a severe procedural complication depending on the location and size, while liquid biopsy is non-invasive, and novel emerging method in lung cancer. In this study, we investigated the sensitivity, specificity, and concordance rate of liquid biopsy (blood and bronchoalveolar lavage fluid (BALF)) comparing with tissue biopsy.Method
A total of 31 patients’ tissue, blood, and BALF were available. The EGFR mutation status in blood, and BALF were investigated by ultrasensitive droplet-digital polymerase chain reaction (ddPCR) method. We applied two QC criteria for the results of ddPCR were used as previous study showed: 1) the droplet number must be greater than 9000; 2) the wild type levels to be greater than 100 copies/mL.Result
Female was 15 (48.4%) and mean age was 66.4 ± 9.6. Clinical sensitivity was 20.0% [2/10] for E19del and 36.4% [4/11] for L858R in plasma, while in BALF, those was 70.0% and 81.8%, respectively. The concordance rates of plasma with tissue-based results of EGFR mutations were 71.0% for E19del and 77.4% for L858R. In BALF, those were 83.9% for E19del, and 90.3% for L858R. The area under the curve (AUC) for E19del was 0.576 in blood and 0.802 in BALF. The AUC for L858R was 0.682 in blood and 0.884 in BALF. The values of AUC between blood and BAL did not show significant difference.Conclusion
BALF could be a substitute for biopsy in EGFR genotyping and BALF might be helpful in diagnosis of lung cancer in situations where it is difficult to perform biopsy or rebiopsy is needed. Further prospective large scaled studies are needed to investigate the utility of BAL in lung cancer.